ACORQ
vs
S&P 500
ACORQ
S&P 500
Over the past 12 months, ACORQ has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +16% growth.
Stocks Performance
ACORQ vs S&P 500
Performance Gap
ACORQ vs S&P 500
Performance By Year
ACORQ vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Acorda Therapeutics Inc
Glance View
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Ardsley, New York and currently employs 118 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). INBRIJA is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. INBRIJA utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
